CVAid Medical is a health care startup based in Israel, founded in 2018 with a focus on the research and development of AI based innovative stroke diagnosis technologies and full cycle disease management concepts. Their slogan "Research and development of AI based innovative stroke diagnosis technologies and full cycle disease management concepts" embodies their dedication to advancing medical practice. CVAid's mission is to lead the field of Tele-stroke, improve medical practice, and spread their advanced technologies worldwide to save lives.
At CVAid, the expertise is invested in the research and development of innovative stroke diagnosis and full cycle disease management concepts, encompassing pre-hospital early diagnosis, in-hospital process management, and post-hospital discharge follow-up. This forward-thinking approach advances the field of Tele-stroke and evolves into state-of-the-art solutions that define the next generation of stoke disease management and patient care.
The company recently secured a $4.00M Series A investment on 28th February 2022, with backing from notable investors including Sanara Ventures, Philips, and RAD BioMed Accelerator. This milestone investment demonstrates confidence in CVAid's potential for growth and impact in the healthcare industry.
No recent news or press coverage available for CVAid Medical.